



Atty. Docket:UCONAP/141/US

In re patent application of first named inventor: Alexandros Makriyannis et al

Application No.: 09/328,742 Examiner: A. N. Pryor

Filing Date: June 6, 1999 Group Art Unit: 1616

For: Inhibitors Of The Anandamide Transporter As Analgesic Agents

### TRANSMITTAL LETTER

Commissioner for Patents, U.S. Patent and Trademark Office, 2011 South Clark Place,  
Customer Window, Crystal Plaza 2, Lobby, Room 1B03, Arlington, VA 22202

Sir, enclosed herewith is (are):

- Information Disclosure Statement
- check for \$180.00
- return postcard

It is hereby petitioned that any required extension of time be granted for filing the enclosed papers. An extension of 0 month(s) having a fee of \$0 appears required.

☒ If checked, claims are being amended.

	No. of claims remaining after amendment	Highest no. of claims previously paid for	no. extra	claim fee	subtotal
Total				\$	\$0.00
Independent				\$	\$0.00
Total claim fees					\$ 0.00

☒ If checked, a check in the amount of \$180.00 is attached. Please credit any overpayment to Deposit Account 16-2563 of Alix, Yale & Ristas, LLP.

The Commissioner is hereby requested and authorized to charge Deposit Account 16-2563 of Alix, Yale & Ristas, LLP for any required extension fee and for any other fee, not enclosed herewith, due for any reason during the pendency of this application or in connection with the accompanying document, including (a) any filing fees under 37 CFR 1.16 for the presentation of extra claims and (b) any patent application processing fees under 37 CFR 1.17. A duplicate copy of this letter is enclosed.

Date: 6/25/04  
Alix, Yale & Ristas, LLP  
750 Main Street- Suite 1400  
Hartford, CT 06103-2721  
(860) 527-9211

By: [Signature]  
James E. Piotrowski  
Registration No. 43,860  
Attorney for Applicant

JEP/kcs/enclosures

G:\AYR saved docs\Filing Docs\Uconap\uconap141us\uconap141us 5-04 ids transmittal.doc



Attorney Docket: UCONAP/141/US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of: Alexandros Makriyannis et al

Application No.: 09/328,742 Examiner: Pryor, Alton Nathaniel

Filing Date: 06/06/1999 Group Art Unit: 1616

For: Inhibitors of the Anandamide Transporter as Analgesic Agents

Commissioner for Patents, U.S. Patent and Trademark Office, 2011 South Clark  
Place, Customer Window, Crystal Plaza 2, Lobby, Room 1B03, Arlington, VA 22202

Sir:

**Information Disclosure Statement**

Applicant submits herewith patents, publications or other information of which they are aware and which they believe may be material to the examination of the above-identified application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(b) exists.

For US national applications filed after June 30, 2003 and International applications that have entered the national stage after June 30, 2003 a copy of a cited US patent or cited US patent publication is NOT required. See OG Notices: 5 August 2003.

06/30/2004 CCHAU1 00000075 09328742

01 FC:1806

180.00 OP

AYR 11/03

Accordingly, no copies of a cited US patent or cited US patent publication are enclosed for these applications. A copy of each item other than a US patent or a US patent publication listed on the attached INFORMATION DISCLOSURE CITATION IN AN APPLICATION is supplied herewith.

For US national applications filed before June 30, 2003 and International applications that have entered the national stage before June 30, 2003 a copy of each of the items listed on the attached INFORMATION DISCLOSURE CITATION IN AN APPLICATION is supplied herewith.


Citations in bold type and having a name preceded with \*1\* indicate references which are believed to be more closely related to the claimed subject matter. This indication is not meant to indicate or imply any position with respect to the remaining references.

Citations in italics and having a name preceded with \*\*\* indicate references for which Applicant has no copy to submit. If a copy of any of these references is procured the same will be filed in a subsequent IDS.

Respectfully submitted,


Alexandros Makriyannis et al

Date: 6/25/04  
750 Main Street- Suite 1400  
Hartford, CT 06103-2721  
(860) 527-9211

By:   
James E. Piotrowski  
Registration No. 43,860  
Alix, Yale & Ristas, LLP  
Attorney for Applicants




<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>		Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
		Filing Date 06/06/1999		Group Art Unit 1616	
<b>UNITED STATES PATENT DOCUMENTS</b>					
Examiner Initial	Document No.	Date	Name		Class
	10/110865	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28497 enclosed herewith)		
	10/110830	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28329 enclosed herewith)		
	10/110812	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28498 enclosed herewith)		
	10/110862	10/18/00	<b>*1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/29007 enclosed herewith)</b>		
	10/111059	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28557 enclosed herewith)		
	2002/0119972	8/29/02	Leftheris et al		
	2003/0120094	6/26/03	Makriyannis et al		
	3041343	6/26/62	Jucker et al		
	3573327	3/30/71	Miyano		
	3656906	4/18/72	Bullock		
	3886184	5/27/75	Matsumoto et al		
	3897306	7/29/75	Vidic		
	3915996	10/28/75	Wright		
	3928598	12/23/75	Archer		
	3944673	3/16/76	Archer		
	3953603	4/27/76	Archer		
	4036857	7/19/77	Razdan et al		



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>			Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
			Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
			Filing Date 06/06/1999		Group Art Unit 1616	


	4054582	10/18/77	Blanchard et al	
	4087545	5/2/78	Archer et al	
	4087546	5/2/78	Archer et al	
	4087547	5/2/78	Archer et al	
	4088777	5/9/78	Archer et al	
	4102902	7/25/78	Archer et al	
	4152450	5/1/79	Day et al	
	4171315	10/16/79	Ryan et al	
	4176233	11/27/79	Archer et al	
	4179517	12/18/79	Mechoulam	
	4188495	2/12/80	Althuis et al	
	4208351	6/17/80	Archer et al	
	4278603	7/14/81	Thakkar et al	
	4282248	8/4/81	Mechoulam et al	
	4382943	5/10/83	Winter et al	
	4395560	7/26/83	Ryan	
	4550214	10/29/85	Mehta	
	4758597	7/19/88	Martin et al	
	4876276	10/24/89	Mechoulam	
	4885295	12/5/89	Bell et al	
	5053548	10/1/91	Tanaka et al	
	5068234	11/26/91	D'Ambra et al	
	5147876	9/15/92	Mizuchi et al	
	5223510	6/29/93	Gubin et al	
	5284867	2/8/94	Kloog	
	5324737	6/28/94	D'Ambra et al	
	5434295	7/18/95	Mechoulam et al	
	5440052	8/8/95	Makriyannis et al	
	5462960	10/31/95	Barth et al	
	5489580	2/6/96	Makriyannis et al	
	5521215	5/28/96	Mechoulam	
	5532237	7/2/96	Gallant et al	
	5538993	7/23/96	Mechoulam	
	5605906	2/25/97	Lau	
	5607933	3/4/97	D'Ambra et al	
	5624941	4/29/97	Barth et al	
	5635530	6/3/97	Mechoulam	



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>			Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
			Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
			Filing Date 06/06/1999		Group Art Unit 1616	
	5747524	5/5/98	Cullinan et al			
	5744459	4/28/98	Makriyannis et al			
	5817651	10/6/98	D'Ambra et al			
	5872148	2/16/99	Makriyannis et al			
	5925768	7/20/99	Barth et al			
	5932610	8/3/99	Shohami et al			
	5948777	9/7/99	Bender et al			
	6013648	1/11/00	Rinaldi et al (appears equivalent to FR2735774)			
	6028084	2/22/00	Barth et al			
	6096740	9/1/00	Mechoulam			
	6127399	10/3/00	Yuan			
	6166066	12/26/00	Makriyannis et al			
	6284788	10/4/01	Mittendorf et al (appears equivalent to EP860168)			
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initial	Document No.	Date	Country	Name		Translation
	EP0276732	8/3/88	EP	Hoffman La Roche		
	EP0471609	6/29/93	EP	Gubin et al, in French, front page only (English bibliography and abstract, appears equivalent to US5223510)		
	EP0737671	10/16/96	EP	<b>*1* Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)</b>		
	EP0860168	9/4/01	EP	Mittendorf et al, in German, front page only (including English bibliography, appears equivalent to US6284788)		



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>				Application No. 09/328,742		Inventor Alexandros Makriyannis et al			
				Title Inhibitors of the Anandamide Transporter as Analgesic Agents					
				Filing Date 06/06/1999		Group Art Unit 1616		Docket No. UCONAP/141/US	
	FR2240003	5/27/75	FR	Matsumoto et al, in French (including English bibliography and abstract, appears equivalent to US3886184)					
	FR2735774	1/11/00	FR	Barth et al, in French (including English bibliography and abstract, appears equivalent to US6013648)					
	GB2027021A	2/13/80	GB	Mechoulam et al, in English (appears equivalent to US4282248)					
	JP2304080	12/17/90	JP	Nakayama Hajime et al, in Japanese (including English bibliography and abstract)					
	JP57098228	6/18/82	JP	Noda et al, in Japanese (including English bibliography and abstract)					
	<b>WO 00/32200</b>	<b>6/8/00</b>		<b>*1* Makriyannis et al, in English</b>					
	WO 01/28329	4/26/01		Makriyannis et al, in English					
	WO 01/28497	4/26/01		Makriyannis et al, in English					
	WO 01/28498	4/26/01		Makriyannis et al, in English					
	WO 01/28557	4/26/01		Makriyannis et al, in English					
	WO 01/29007	4/26/01		Makriyannis et al, in English					
	WO 01/32169	5/10/01		Fride et al, in English					
	WO 01/58869	8/16/01		Pandit et al, in English, first page only (including bibliography and abstract, appears equivalent to US2002/0119972)					
	WO 97/00860	1/9/97		Rinaldi et al, in French (including English bibliography and abstract, appears equivalent to US6013648)					
	WO 99/57107	11/11/99		Makriyannis et al, in English					



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>		Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
		Filing Date 06/06/1999		Group Art Unit 1616	Docket No. UCONAP/141/US
	WO 99/64389	12/16/99		*1* Makriyannis et al, in English	
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)					
Examiner Initial					
	Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768				
	*** Archer et al; "cannabinoids, synthesis approaches to 9-ketocannabinoids."; J. Org. Chem.; vol. 42; no. 13; 2277-2284; (1977)				
	Amone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacol, (1997) 132, 104-106. ( <b>abstract only</b> )				
	Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36				
	Belgaonkar et al; "synthesis of isocoumarins"; Indian J. Chem; vol. 13; no. 4; 336-338; 1975 ( <b>abstract only</b> )				
	Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1-2):169-90				
	Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; "Synthesis of 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines"; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 ( <b>abstract only</b> )				
	Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered 9 – tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. ( <b>abstract only</b> )				
	*** Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876.				
	Brown et al; "Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes"; J. Org. Chem.; 55(4); 1217-1223; (1990)				



**INFORMATION DISCLOSURE  
CITATION IN AN  
APPLICATION**

Application No.  
09/328,742

Inventor  
Alexandros Makriyannis et al

Title  
Inhibitors of the Anandamide Transporter as Analgesic Agents

Filing Date  
06/06/1999

Group Art Unit  
1616

Docket No.  
UCONAP/141/US

Buckley NE, McCoy KI, Mpzey E et al, "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor"; Eur. J Pharmacol (2000) 396:141-149.

Burstein et al; "detection of cannabinoid receptors . . ."; Biochem. Biophys. Res. Commun.; vol. 176(1); 492-497; 1991 **(abstract only)**

Busch-Peterson et al; "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs"; J. Med. Chem.; 39; 3790-3796; (1996)

Calignano A, La Rana G, Diufrida A, Piomelli D; "Control of pain initiation by endogenous cannabinoids"; Nature (1998) 394:277-291. **(abstract only)**

Campbell FA et al; "Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review"; BMJ. 2001 Jul 7;323(7303):13-6

Charalambous A. et al; "5'-azido 8-THC: A Novel Photoaffinity Label for the Cannabinoid Receptor"; J. Med. Chem., 35, 3076 - 3079 (1992)

Charalambous A. et al; "Pharmacological evaluation of halogenated . . ."; Pharmacol. Biochem. Behav.; vol. 40; no. 3; 509-512; 1991

Cheng et al; "Relationship Between the Inhibition Constant (Ki) and the concentration of Inhibitor which causes 50% Inhibition (IC50) of an Enzymatic Reaction"; Biochem. Pharmacol., 22, 3099-3102, (1973) **(abstract only)**

Colombo G, Agabio R, Diaz G. et al; "Appetite suppression and weight loss after the cannabinoid antagonist SR141716"; Life Sci. (1998) 63-PL13-PL117. **(abstract only)**

Compton et al; "Synthesis and pharmacological evaluation of ether and related analogues of delta8-, delta9- and delta9,11-tetrahydrocannabinol"; J. Med. Chem; vol. 34; no. 11; 3310-3316; 1991

Consroe P, Musty R, Rein J, Tillery W, Pertwee R; "The perceived effects of smoked cannabis on patients with multiple sclerosis"; Eur. Neurol. (1997) 38-44-48. **(abstract only)**

Coxon et al; "Derivatives of nopinone"; Aust. J. Chem.; 23; 1069-1071; (1970) **(abstract only)**

Crawley et al; "Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents"; Pharmacology Biochemistry and Behavior; vol. 46; 967-972; 1993

D'Ambra et al; "C-attached aminoalkylindoles: potent cannabinoid mimetics"; Bioorg. & Med. Chem. Lett., 1996, 6(1), 17-22





INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	DePetrocellis L, Melck D, Palmisano A. et al; "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation"; Proc. Natl. Acad. Sci. USA (July 1998) 95:8375-8380.		
	Devane, W.A. et al; "Determination and Characterization of a Cannabinoid Receptor in a Rat Brain"; Mol. Pharmacol., 34, 605 - 613 (1988). <b>(abstract only)</b>		
	Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L.; "Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action"; Trends Neurosci. (1998) 21:521 - 528.		
	*** Dodd, P.R. et al, <i>A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures</i> , Brain Res., 226, 107 - 118 (1981).		
	Dominiani et al; "Synthesis of 5-(tert-Alkyl)resorcinols"; J. Org. Chem. 42(2); 344-346; (1977)		
	Drake et al, "classical/nonclassical hybrid cannabinoids"; J. Med. Chem.; vol. 41(19); 3596-3608 (1998)		
	Edery et al; "Activity of novel aminocannabinoids in baboons"; J. Med. Chem.; 27; 1370-1373 (1984)		
	Eissenstat et al; "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics"; J. Med. Chem. 1995, Vol. 38, No. 16, pp. 3094-3105; XP 000651090		
	Fahrenholtz, K. E., Lurie, M. and Kierstead, AR. W.; "The Total Synthesis of dl- $\Delta^9$ -Tetrahydrocannabinol and Four of Its Isomers"; J. Amer. Chem. Soc. 1967, 89(23), 5934-5941		
	Fahrenholtz; "The synthesis of 2 metabolites of (-)-delta eight-tetrahydrocannabinol"; J. Org. Chem.; vol. 37(13); 1972; XP002111824		
	Fisera, L., Kovac, J., Lesco, J., Smahovsky, V.; "Furan derivatives. Part CLVI. 1,3-dipolar cycloadditions of heterocycles. V. Reaction of C-acetyl-N-phenylnitrilimine with furan derivatives"; Chemicke Zvesti; 35(1); 93-104 1981 <b>(abstract only)</b>		
	Galiegue S et al. ; "Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations"; Eur J Biochem.; 1995 Aug 15;232(1):54-61. <b>(abstract only)</b>		
	Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M.; "Structure activity relationships of tetrahydrocannabinol analogs on human cannabinoid receptors"; Bioorg. Med. Chem. Lett. 1996, 6(2), 189-194		



INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	Gold et al; "A comparison of the discriminative stimulus properties of delta9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys"; J. Pharmacol. Exp. Ther.; vol. 262(2); 479-486; 1992		
	*** Green K. Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch. Ophibalmol. (1998) feb 433-1437.		
	Hampson, A.J., Grimaldi M. Axpirod J. Wink D; "Cannabidiol and (-) 9 tetrahydrocannabinol are neuroprotective antioxidants"; Proc. Natl Acad Sci. USA (July 1998) 95; 8268-8273.		
	Hargreaves, K. et al; "A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia"; Pain; 32; 77-88; (1988) (abstract only)		
	*** Hemming M, Yellowlees PM; "Effective treatment of Tourette's syndrome with marijuana"; J. Psychopharmacol, (1993) 7:389-391.		
	Herzberg U, Eliav E, Bennett GJ, Kopin IJ; "The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain"; Neurosci. Letts. (1997) 221; 157-160.		
	<b>*1* Horrevoets A.J.G et al; "Inactivation of reconstituted escherichia coli outer membrane phospholipase A by membrane-perturbing peptides results in an increased reactivity towards the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 255-261; 1991</b>		
	Howlett et al; "Azido and isothicyanato substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction"; Journal of Neurochemistry; vol. 74(5) (2000) 2174-2181; XP001097394		
	Howlett et al; "Stereochemical effects of 11-OH-delta 8 tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor"; Neuropharmacology; vol. 29(2); 161-165; 1990		
	Huffman et al; "3-(1',1'-dimethylbutyl)--deoxy-delta 8THC and related compounds: synthesis of selective ligands for the CB2 receptor"; Bioorganic and Medicinal Chemistry; vol. 7; 2905-2914; (1999)		
	Huffman et al; "Stereoselective synthesis of the epimeric delta 7-tetrahydocannabinols"; tetrahedron; vol. 51(4); 1017-1032; (1995)		
	Huffman et al; "Synthesis of 5',11 dihydroxy delta 8 tetrahydrocannabinol"; Tetrahedron, vol. 53(39), pp 13295-13306 (1997)		
	Huffman et al; "Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC"; Bioorganic & Medicinal Chemistry; vol. 6(12); 2281-2288; 1998; XP002123230		

**INFORMATION DISCLOSURE  
CITATION IN AN  
APPLICATION**

Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US




	Huffman et al; "Synthesis of both enantiomers of Nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids"; J. Org. Chem.; 1991, 56, 2081-2086
	*** Joy JE, Wagtson SJ, Benson JA; <i>"Marijuana and Medicine Assessing the Science Base"</i> ; National Academy Press, Washington, DC, USA (1999).
	Kaminski NE; "Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors"; J Neuroimmunol. 1998 Mar 15;83(1-2):124-32
	Khanolkar et al; "Molecular probes for the cannabinoid receptors"; Chemistry and Physics of Lipids; 108; 37-52; (2000)
	Klein T.W. et al, "The cannabinoid system and cytokine network"; Proc Soc Exp Biol Med. 2000 Oct; 225(1):1-8; <b>(abstract only)</b>
	Klein TW et al, "Cannabinoid receptors and immunity"; Immunol Today; 1998 Aug; 19(8):373-81
	Kumar RN, et al; "Pharmacological actions and therapeutic uses of cannabis and cannabinoids"; Anesthesia, 2001, 56: 1059-1068 <b>(abstract only)</b>
	Lan, R et al; "Structure activity relationships of pyrazole derivatives as cannabinoid receptor antagonists"; J. Med. Chem.; vol. 42(4); 769-776; (1999)
	Lavalle et al; "Efficient conversion of (1R, 5R)-(+)-alpha-pinene to (1S, 5R)-(-)-nopinene"; J. Org. Chem.; vol. 51(8); 1362-1365; (1986)
	Loev, B., Bender, P. E., Dowalo, F., Macko, E., and Fowler, P.; "Cannabinoids. Structure-Activity Studies Related to 1,2-Dimethylheptyl Derivatives"; J. Med. Chem.; vol. 16(11); 1200-1206; 1973
	Lozinskii, M.O., Bodnar, V.N., Konovalikhin, S.V., D'yachenko, O.A., Atovmyan, L.O.; "Unusual transformations of arylhydrazonoyl chlorides of oxalic acid ethyl ester"; Izvestiya Akademii Nauk SSSr, Seriya Khimicheskaya; 11; 2635-2637; 1990 <b>(abstract only)</b>
	Ludt, R.E. et al; "A comparison of the synthetic utility of n-butyllithium and lithium diisopropylamide in the metalations of N,N-dialkyltouamides"; J. Org. Chem.; 38(9); 1668-1674 (1973)
	*** Maccarron M., <i>Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255</i>
	*** Markwell et al; <i>Anal. Biochem.</i> ; 87:206 (1978)
	Martin et al; "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs"; Pharmacol. Biochem. Behav.; vol. 40(3); 471-478; 1991



INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
E SC171 2004 REMARK OFFICE	Martyn CN. Illis LS, Thom J.; "Nabilone in the treatment of multiple sclerosis"; Lancet (1995) vol. 345; pp. 579.		
	Matsumoto et al; "Cannabinoids 1.1-amino-and 1 mercapto-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyrans"; J. of Med. Chem.; vol. 20(1); 17-24; 1977; XP00211825		
	*** Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiat. Clin. Neurosci. (1990), Z40:1-4.		
	Mavromoustakos, T. et al; "Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction"; Biochimica et Biophysica Acta; vol 1281(2); 1996; XP00211823		
	Mechoulam et al; "Stereochemical Requirements for cannabinoid activity"; J. Med. Chem.; 23(10); 1068-1072; (1980)		
	Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative"; Tetrahedron Asymmetry; 1: 311-314; (1990) (abstract only)		
	*** Mechoulam et al; Tetrahedron Asymmetry; 1: 315-318; (1990)		
	*** Mechoulam, "Cannabinoids as therapeutic agents"; CRC press, 1986		
	Meltzer et al; "An improved synthesis of cannabinol and cannabiorcol"; Synthesis; 1981:985 (1981)		
	*** Melvin et al; drug design and discovery; 13; 155-166 (1995)		
	Melvin et al; "Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs"; Mol. Pharmacol.; 44(5); 1008-1015 (1993)		
	Merck Index; 11th edition; "Tetrahydrocannabinols" compound no. 9142; 1989		
	*** Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997).		
	*** Morris, S.; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc., Perkin Trans. 1 1987, 1423-1427		
	*** Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27.		
	*** Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195.		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	*** <i>Nahas G, Marijuana and Medicine; 1999, Human Press Inc., Totowa, NJ</i>		
	Novak, J et al; "Cannabis, part 27, synthesis of 8-, 10- and 11-oxygenated cannabinoids; J. Chem. Soc. Perkin Trans.; 2867-2871; (1983) ( <b>abstract only</b> )		
	Nye et al; "High affinity cannabinoid binding sites in brain membranes labelled with [H]-5'-trimethylammonium delta8-tetrahydrocannabinol"; J. Pharmacol. Exp. Ther.; vol. 234(3); 784-791; 1985		
	*** <i>Palmer et al; current pharmaceutical design; 6; 1381-1397; (2000)</i>		
	Papahatjis et al; "A new ring-forming methodology for the synthesis of conformationally constrained bioactive molecules"; Chemistry Letters, 192; (2001)		
	Papahatjis et al; "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta8-tetrahydrocannabinols"; J. Med. Chem.; 41(7); 1195-1200; (1998)		
	Pertwee et al; "AM630, a competitive cannabinoid receptor agonist"; Life Sci. 1995, 56(23/24), 1949-1955; XP 000653566		
	Pertwee et al; "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens"; Eur. J. Pharmacol. 1995, 284, 241-247; XP-001041044		
	Pertwee; Pharmacology of cannabinoid CB1 and CB2 receptors"; Pharmacol. Ther., vol. 74(2); pp129-180; (1997); XP002226467		
	Petrov, M.L., Terent'eva, N.A., Potekhin, K.A., Struchkov, Yu. T.; ".alpha.,.beta.-unsaturated thiolates and their analogs in cycloaddition reactions. XVIII. Reaction of (2-phenylethynyl)tellurolates with C-ethoxycarbonyl-N-Phenylnitrilimine"; Zhurnal Organicheskoi Khimii; 29(7); 1372-1378; (1993) ( <b>abstract only</b> )		
	*** <i>Pinnegan-Ling D, Musty R.; Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53.</i>		
	Pitt et al; "The synthesis of Deuterium, carbon-14 and carrier free tritium labelled cannabinoids"; Journal of Labelled Compounds; vol. 11(4); 551-575; 1975; XP002123229		
	Razdan et al; "Drugs delivered from cannabinoids. 6. .Synthesis of cyclic analogues of dimethylheptylpyran"; J. Med. Chem.; vol. 19(5); 719-721; 1976 ( <b>abstract only</b> )		
	Reggio et al; "Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach"; J. Med. Chem. United States; vol. 36(12); 1761-1771; 1993		



INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R.; "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylcyclase"; J. Med. Chem. 1997, 40(20); 3228-3233		
	*** Rice AS. <i>Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414</i>		
	Richardson JD, Aanonsen I, Hargreaves KM; "Antihyperalgesic effects of spinal cannabinoids"; Eur. J. Pharmacol. (1998) 346:145-153.		
	Richardson JD, Kilo S. Hargreaves KM; "Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors"; Pain (1998) 75:111-119.		
	Rinaldi-Carmona et al; "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"; Life Sci.; vol. 56(23/24); 1941-1947 (1995)		
	Rinaldi-Carmona et al; "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"; FEBS Lett.; 350; 240-244; (1994)		
	Rompp Chemie Lexikon; Falbe and Regitz; "band 1-A-C1, 8"; Aufl, Thieme Verlag; Stuttgart, S 569-570; 1989		
	Santus, Maria; "Studies on thioamides and their derivatives. IX. Synthesis of the derivatives of 1,2,4,5-tetrazine"; Acta Polonae Pharmaceutica; 50(2-3); 183-188; 1993 ( <b>abstract only</b> )		
	Schatz AR et al; "Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system"; Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87		
	*** Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., <i>Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8), 325a.</i>		
	Shawali, A.S., Albar, H.A.; "Kinetics and mechanism of dehydrochlorination of N-aryl-C-ethoxycarbonyl formohydrazidoyl chlorides"; Canadian Journal Of Chemistry; 64(5); 871-875; 1986 ( <b>abstract only</b> )		
	*** Shen M. Thayer SA: <i>Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.</i>		
Shim et al; "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis"; J. Med. Chem.; 1998, 41(23); 4521-4532; XP-002212407			





INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	Shim et al; "Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2"; ACS Symposium series, 1999 719 (rational drug design), 165-184; XP-001095771		
	Showalter et al; "Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands"; J. Pharmacol. Exp. Ther., 1996 278(3) 989-999; XP-001097918		
	*** Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181.		
	*** Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172.		
	Tius et al; "Conformationally restricted hybrids of CP-55,940 and HHC: Stereoselective synthesis and activity"; Tetrahedron; 50 (9); 2671-2680; (1994) (abstract only)		
	*** Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68-69:521-534		
	*** Wagner JA, Varga K, Jarai Z, Kunos G; 'Mesenteric vasodilation mediated by endothelial anandamide receptors'; Hypertension (1999) 33:429-434.		
	Watanabe, T.; Miyaura, N.; and Suzuki, A.; "Synthesis of Sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes"; Synlett 1992, 207-210		
	Wiley et al; "Structure activity relationships of indole and pyrrole derived cannabinoids"; J. Pharmacol. Exp. Ther. 1998, 285(3), 995-1004; XP-001097982		
	Wilson et al; "9-nor-delta8-tetrahydrocannabinol, a cannabinoid of metabolic interests"; J. Med. Chem.; 17(4); 475-476; (1974)		
	Wilson et al; "Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs"; J. Med. Chem.; 18(7); 700-703; (1975)		
	Wilson et al; "9-nor-9-hydrohexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols"; J. Med. Chem.; 19(9); 1165-1167; (1976)		



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	Yamada et al; "(Aminoalkyl)indole isothiocyanates as potential electrophilic affinity ligands for the brain cannabinoid receptor"; J. Med. Chem. 1996, vol. 39(10), 1967-1974		
	Yan, Guo et al; "Synthesis and pharmacological properties of 11-hydroxy-3-(1'-1'-dimethylheptyl)hexahydrocannabinol: a high affinity cannabinoid agonist"; J. Med. Chem.; vol. 37(16); 2619-2622; (1994)		
	Yan Guo et al; "(-)-11-hydroxy-7'-isothiocyanato-1'-1'-dimethylheptyl-delta8-THC: a novel probe for the cannabinoid receptor in the brain"; J. Med. Chem.; 37(23); 3867-3870; (1994)		
Examiner		Date Considered	
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

